Literature DB >> 19062176

Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells.

Monika Szeliga1, Marta Obara-Michlewska, Ewa Matyja, Marzena Łazarczyk, Carolina Lobo, Wojciech Hilgier, Francisco J Alonso, Javier Márquez, Jan Albrecht.   

Abstract

Liver-type glutaminase (LGA) is a glutaminase isoform that has been implicated in transcription modulation. LGA mRNA is absent from postoperative samples of primary gliomas and is low in cultured astrocytes. In this study, stable transfection of T98G cells with a vector carrying human LGA sequence increased the expression of LGA mRNA and protein, and the ability of the cells to degrade glutamine (Gln), as manifested by a three-fold reduction of their steady-state Gln content and a 2.5-fold increase of their glutamate (Glu) content. The transfected cells (TLGA cells) showed a 40% decrease of cell survival as assessed by colony formation, well correlated with significant reduction of mitochondrial activity as demonstrated with MTT test. Also, a 45% reduction of cell migration and a 47% decrease of proliferation index (Ki67 immunostaining) were found as compared with sham-transfected cells. Microarray analysis, which included over 47,000 transcripts, revealed a significantly altered expression of 85 genes in TLGA, but not in sham-transfected or control cells (P < 0.005). Microarray data were confirmed with real-time PCR analysis for eight genes potentially relevant to malignancy: S100A16, CAPN2, FNDC3B, DYNC1LI1, TIMP4, MGMT, ADM, and TIMP1. Of these changes, decreased expression of S100A16 and MGMT can be best reconciled with the current views on the role of their protein products in glioma malignancy. Malignancy-reducing effect of newly inserted LGA mRNA in glioblastoma cells can be reconciled with a hypothesis that absence of such a modulatory mechanism in glia-derived tumors deprived of LGA mRNA may facilitate some aspects of their progression. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19062176     DOI: 10.1002/glia.20825

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  23 in total

1.  Understanding the non-canonical pathways involved in p53-mediated tumor suppression.

Authors:  Kayla M Hager; Wei Gu
Journal:  Carcinogenesis       Date:  2013-12-31       Impact factor: 4.944

Review 2.  Mammalian glutaminase isozymes in brain.

Authors:  Javier Márquez; Carolina Cardona; José A Campos-Sandoval; Ana Peñalver; Marta Tosina; José M Matés; Mercedes Martín-Rufián
Journal:  Metab Brain Dis       Date:  2012-11-14       Impact factor: 3.584

3.  Proteomics analysis of proteins interacting with heat shock factor 1 in squamous cell carcinoma of the cervix.

Authors:  Lingli Zhang; Zhe Hu; Ying Zhang; Jinzhi Huang; Xuefen Yang; Jiafeng Wang
Journal:  Oncol Lett       Date:  2019-06-27       Impact factor: 2.967

4.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.

Authors:  Wenwei Hu; Cen Zhang; Rui Wu; Yvonne Sun; Arnold Levine; Zhaohui Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

5.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation.

Authors:  Jian-Bin Wang; Jon W Erickson; Reina Fuji; Sekar Ramachandran; Ping Gao; Ramani Dinavahi; Kristin F Wilson; Andre L B Ambrosio; Sandra M G Dias; Chi V Dang; Richard A Cerione
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

6.  Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma.

Authors:  Apostolos Zaravinos; Peggy Kanellou; George I Lambrou; Demetrios A Spandidos
Journal:  Tumour Biol       Date:  2014-01-31

Review 7.  A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.

Authors:  William P Katt; Michael J Lukey; Richard A Cerione
Journal:  Future Med Chem       Date:  2017-01-23       Impact factor: 3.808

Review 8.  Therapeutic strategies impacting cancer cell glutamine metabolism.

Authors:  Michael J Lukey; Kristin F Wilson; Richard A Cerione
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

Review 9.  Glutamine Addiction In Gliomas.

Authors:  Javier Márquez; Francisco J Alonso; José M Matés; Juan A Segura; Mercedes Martín-Rufián; José A Campos-Sandoval
Journal:  Neurochem Res       Date:  2017-03-09       Impact factor: 3.996

Review 10.  Glutamine at focus: versatile roles in cancer.

Authors:  Humberto De Vitto; Juan Pérez-Valencia; James A Radosevich
Journal:  Tumour Biol       Date:  2015-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.